{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:33:43Z","timestamp":1790692423542,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Linezolid (LNZ) is an effective antibiotic to treat patients with multidrug-resistant tuberculosis (MDR-TB) treatment failure.\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    strains resistant to isoniazid and rifampin are defined as MDR-TB. In recent years, resistance to LNZ among MDR-TB cases has been reported in several different countries. In this study, we performed a systematic review and meta-analysis to investigate the prevalence of LNZ resistance among MDR-TB isolates.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The databases of Embase, PubMed\/Medline, and Web of Science were searched systematically from January 2000 to April 2021. Statistical analyses were performed by using Comprehensive Meta-Analysis software. Heterogeneity was reported by using the t-squared statistic and Q-statistic. Begg\u2019s rank correlation in combination with the funnel plot were used to evaluate any possible publication bias.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In total, 25 studies were selected for meta-analysis from 14 different countries; the majority was from China (n = 5) and Turkey (n = 4). Moreover, 7,366 patients were infected with MDR\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    . Among the study population, 98 patients were co-infected with HIV, and 18 patients with hepatitis C virus (HCV). Furthermore, 28 cases had diabetes, and139 cases were alcohol abuser. Overall, 4,956 MDR\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    strains were isolated from TB patients. The pooled frequency of LNZ resistance among the clinical isolates of MDR\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    was 4.2% (95%). Begg\u2019s (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.72) test showed no evidence of publication bias.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    LNZ resistance among MDR M. tuberculosis isolates is increasing. On the other hand, long-term treatment of MDR-TB cases with LNZ alone is associated with several adverse effects. Thus, it is recommended that newer anti-TB drugs, including bedaquiline and delamanid, in combination with linezolid could increase its effectiveness and decrease toxicities. However, more studies should be done in this field.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.955050","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T16:12:21Z","timestamp":1661875941000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Taher","family":"Azimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahab Hassan","family":"Kaviar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoume","family":"Hallajzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1128\/AAC.02020-12","article-title":"Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate","volume":"57","author":"Ahmed","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1128\/aac.47.1.416-417.2003","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcal\u00e1","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jctube.2018.01.001","article-title":"High genetic diversity among Mycobacterium tuberculosis strains in Tehran, Iran","volume":"11","author":"Azimi","year":"2018","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"B4","first-page":"40","article-title":"Mycobacterium tuberculosis genotyping using MIRU-VNTR typing","volume":"27","author":"Azimi","year":"2017","journal-title":"J. Mazandaran Univ. Med. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5578\/mb.4229","article-title":"Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates","volume":"47","author":"Bekt\u00f6re","year":"2013","journal-title":"Mikrobiyol. Bul."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: A multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jac\/dku438","article-title":"Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study","volume":"70","author":"Cambau","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/jac\/dkx022","article-title":"Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic\/pharmacodynamic parameters","volume":"72","author":"Cavanaugh","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.5588\/ijtld.13.0197","article-title":"Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: An update","volume":"18","author":"Chaiprasert","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B10","first-page":"293","article-title":"Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates","volume":"43","author":"Coban","year":"2009","journal-title":"Mikrobiyol. Bul."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3201\/eid1411.080729","article-title":"Multidrug-and extensively drug-resistant tuberculosis, Germany","volume":"14","author":"Eker","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7860\/JCDR\/2019\/42544.13298","article-title":"Evaluation of sensitivity and resistance of linezolid in pre extensively drug resistance tuberculosis and extensively drug resistance tuberculosis at a tertiary care hospital, jamnagar, Gujarat, India","volume":"13","author":"Gavali","year":"2019","journal-title":"J. Clin. Diagnostic Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1128\/AAC.00414-07","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years","volume":"52","author":"Huang","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","volume-title":"Joanna Briggs Institute reviewers\u2019 manual: 2014 edition","year":"2014"},{"key":"B17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/jcm9020465","article-title":"Whole genome sequencing results associated with minimum inhibitory concentrations of 14 anti-tuberculosis drugs among rifampicin-resistant isolates of mycobacterium tuberculosis from Iran","volume":"9","author":"Kardan-Yamchi","year":"2020","journal-title":"J. Clin. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3906\/sag-1007-934","article-title":"An investigation of the antimicrobial impact of drug combinations against Mycobacterium tuberculosis strains","volume":"41","author":"Limoncu","year":"2011","journal-title":"Turkish J. Med. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1086\/591702","article-title":"Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan","volume":"47","author":"Lai","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00900","DOI":"10.1128\/AAC.00900-17","article-title":"In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1128\/JCM.01500-10","article-title":"Rapid first-and second-line drug susceptibility assay for Mycobacterium tuberculosis isolates by use of quantitative PCR","volume":"49","author":"Pholwat","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijantimicag.2012.11.011","article-title":"In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"41","author":"Rey-Jurado","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12879-019-4211-0","article-title":"Towards tailored regimens in the treatment of drug-resistant tuberculosis: A retrospective study in two Italian reference centres","volume":"19","author":"Riccardi","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1128\/AAC.01113-06","article-title":"First linezolid-resistant clinical isolates of Mycobacterium tuberculosis","volume":"51","author":"Richter","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5578\/mb.8602","article-title":"Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant mycobacterium tuberculosis complex isolates by E-test method","volume":"49","author":"\u015eim\u015fek","year":"2015","journal-title":"Mikrobiyol. Bul."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PLoS Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100175","DOI":"10.1016\/j.jctube.2020.100175","article-title":"Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India","volume":"20","author":"Tornheim","year":"2020","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1179\/joc.2010.22.1.17","article-title":"Linezolid penetration into cerebrospinal fluid and brain tissue","volume":"22","author":"Tsona","year":"2010","journal-title":"J. Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jinf.2021.02.004","article-title":"Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey","volume":"82","author":"Wang","year":"2021","journal-title":"J. Infect."},{"key":"B30","article-title":"Global tuberculosis report 2020: Executive summary","year":"2020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.7883\/yoken.65.240","article-title":"In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China","volume":"65","author":"Yang","year":"2012","journal-title":"Jpn. J. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","article-title":"Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea","volume":"38","author":"Yang","year":"2018","journal-title":"Ann. Lab. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijantimicag.2013.12.007","article-title":"Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China","volume":"43","author":"Zhang","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12879-021-06024-8","article-title":"Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e00165","DOI":"10.1128\/AAC.00165-18","article-title":"Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China","volume":"62","author":"Zong","year":"2018","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.955050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T16:12:32Z","timestamp":1661875952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.955050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":35,"alternative-id":["10.3389\/fphar.2022.955050"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.955050","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"955050"}}